A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma
Gespeichert in:
| Veröffentlicht in: | Blood cancer journal (New York) 2019-07, Vol.9 (8), p.58-5, Article 58 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 8 |
| container_start_page | 58 |
| container_title | Blood cancer journal (New York) |
| container_volume | 9 |
| creator | Spencer, Andrew Walker, Patricia Asvadi, Parisa Campbell, Douglas H. Reed, Kate Herbert, Ben R. Breen, Edmond J. Copeman, Michael C. Dunn, Rosanne D. |
| description | |
| doi_str_mv | 10.1038/s41408-019-0217-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2267390925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-aa3b1ca6fde1a665fe6f9253cfeb78d272cf576bb34d07ae76a8000224c9a6543</originalsourceid><addsrcrecordid>eNp1Uctu1TAUtBCIVpd-ABtkiQ1dGGzHdpINUlXKQ7RiAxI76yRx7nWV2MF2qO6H9Gf6Ef0mnN4-F3jjxzkzZzyD0GtG3zNaVB-iYIJWhLKaUM5KIp-hfU6FILKo5PNH5z10EOM5zUsqVrP6JdorWKFUzcQ-ujzCUzCDHa2DsMUxzd0W-x6njcHgkiXXV3jcmsGPcHNfG4dH73w7eAfDzVPjM-Q7TBOcQYPfnX36TRity0Ns3cKdgoFkOjxBssaliC9s2uDrKxJMTMG2S22ch2SnwdyNeoVe9DBEc3C7r9Cvzyc_j7-S0x9fvh0fnZJWlDQRgKJhLai-MwyUkr1Rfc1l0famKauOl7ztZamaphAdLcGUCqpsA-eirUFJUazQxx3vNDej6dqsL8Cgp2DH7Ib2YPXTirMbvfZ_tVKqElJmgre3BMH_mfOH9LmfQ3Ymas5VWdR00bNCbNfVBh9jMP39BEb1EqbehalzmHoJUy-YN4-l3SPuossNfNcQc8mtTXgY_X_Wf_Tmrpg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2267390925</pqid></control><display><type>article</type><title>A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><creator>Spencer, Andrew ; Walker, Patricia ; Asvadi, Parisa ; Campbell, Douglas H. ; Reed, Kate ; Herbert, Ben R. ; Breen, Edmond J. ; Copeman, Michael C. ; Dunn, Rosanne D.</creator><creatorcontrib>Spencer, Andrew ; Walker, Patricia ; Asvadi, Parisa ; Campbell, Douglas H. ; Reed, Kate ; Herbert, Ben R. ; Breen, Edmond J. ; Copeman, Michael C. ; Dunn, Rosanne D.</creatorcontrib><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/s41408-019-0217-5</identifier><identifier>PMID: 31366914</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/1 ; 13/21 ; 59/78 ; 631/250/249/1623 ; 631/67/1059/2325 ; 631/67/1990/804 ; 631/67/327 ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - pharmacokinetics ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - pharmacokinetics ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Correspondence ; Dose-Response Relationship, Drug ; Hematology ; Humans ; Immunoglobulin kappa-Chains - immunology ; Middle Aged ; Monoclonal antibodies ; Multiple Myeloma - drug therapy ; Multiple Myeloma - immunology ; Multiple Myeloma - microbiology ; Multiple Myeloma - pathology ; Oncology ; Prognosis ; Tissue Distribution</subject><ispartof>Blood cancer journal (New York), 2019-07, Vol.9 (8), p.58-5, Article 58</ispartof><rights>The Author(s) 2019</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-aa3b1ca6fde1a665fe6f9253cfeb78d272cf576bb34d07ae76a8000224c9a6543</citedby><cites>FETCH-LOGICAL-c470t-aa3b1ca6fde1a665fe6f9253cfeb78d272cf576bb34d07ae76a8000224c9a6543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668455/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668455/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31366914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spencer, Andrew</creatorcontrib><creatorcontrib>Walker, Patricia</creatorcontrib><creatorcontrib>Asvadi, Parisa</creatorcontrib><creatorcontrib>Campbell, Douglas H.</creatorcontrib><creatorcontrib>Reed, Kate</creatorcontrib><creatorcontrib>Herbert, Ben R.</creatorcontrib><creatorcontrib>Breen, Edmond J.</creatorcontrib><creatorcontrib>Copeman, Michael C.</creatorcontrib><creatorcontrib>Dunn, Rosanne D.</creatorcontrib><title>A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer J</addtitle><addtitle>Blood Cancer J</addtitle><subject>13/1</subject><subject>13/21</subject><subject>59/78</subject><subject>631/250/249/1623</subject><subject>631/67/1059/2325</subject><subject>631/67/1990/804</subject><subject>631/67/327</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Agents, Immunological - pharmacokinetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Correspondence</subject><subject>Dose-Response Relationship, Drug</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunoglobulin kappa-Chains - immunology</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - immunology</subject><subject>Multiple Myeloma - microbiology</subject><subject>Multiple Myeloma - pathology</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Tissue Distribution</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1Uctu1TAUtBCIVpd-ABtkiQ1dGGzHdpINUlXKQ7RiAxI76yRx7nWV2MF2qO6H9Gf6Ef0mnN4-F3jjxzkzZzyD0GtG3zNaVB-iYIJWhLKaUM5KIp-hfU6FILKo5PNH5z10EOM5zUsqVrP6JdorWKFUzcQ-ujzCUzCDHa2DsMUxzd0W-x6njcHgkiXXV3jcmsGPcHNfG4dH73w7eAfDzVPjM-Q7TBOcQYPfnX36TRity0Ns3cKdgoFkOjxBssaliC9s2uDrKxJMTMG2S22ch2SnwdyNeoVe9DBEc3C7r9Cvzyc_j7-S0x9fvh0fnZJWlDQRgKJhLai-MwyUkr1Rfc1l0famKauOl7ztZamaphAdLcGUCqpsA-eirUFJUazQxx3vNDej6dqsL8Cgp2DH7Ib2YPXTirMbvfZ_tVKqElJmgre3BMH_mfOH9LmfQ3Ymas5VWdR00bNCbNfVBh9jMP39BEb1EqbehalzmHoJUy-YN4-l3SPuossNfNcQc8mtTXgY_X_Wf_Tmrpg</recordid><startdate>20190731</startdate><enddate>20190731</enddate><creator>Spencer, Andrew</creator><creator>Walker, Patricia</creator><creator>Asvadi, Parisa</creator><creator>Campbell, Douglas H.</creator><creator>Reed, Kate</creator><creator>Herbert, Ben R.</creator><creator>Breen, Edmond J.</creator><creator>Copeman, Michael C.</creator><creator>Dunn, Rosanne D.</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20190731</creationdate><title>A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma</title><author>Spencer, Andrew ; Walker, Patricia ; Asvadi, Parisa ; Campbell, Douglas H. ; Reed, Kate ; Herbert, Ben R. ; Breen, Edmond J. ; Copeman, Michael C. ; Dunn, Rosanne D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-aa3b1ca6fde1a665fe6f9253cfeb78d272cf576bb34d07ae76a8000224c9a6543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>13/1</topic><topic>13/21</topic><topic>59/78</topic><topic>631/250/249/1623</topic><topic>631/67/1059/2325</topic><topic>631/67/1990/804</topic><topic>631/67/327</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Agents, Immunological - pharmacokinetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Correspondence</topic><topic>Dose-Response Relationship, Drug</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunoglobulin kappa-Chains - immunology</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - immunology</topic><topic>Multiple Myeloma - microbiology</topic><topic>Multiple Myeloma - pathology</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spencer, Andrew</creatorcontrib><creatorcontrib>Walker, Patricia</creatorcontrib><creatorcontrib>Asvadi, Parisa</creatorcontrib><creatorcontrib>Campbell, Douglas H.</creatorcontrib><creatorcontrib>Reed, Kate</creatorcontrib><creatorcontrib>Herbert, Ben R.</creatorcontrib><creatorcontrib>Breen, Edmond J.</creatorcontrib><creatorcontrib>Copeman, Michael C.</creatorcontrib><creatorcontrib>Dunn, Rosanne D.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spencer, Andrew</au><au>Walker, Patricia</au><au>Asvadi, Parisa</au><au>Campbell, Douglas H.</au><au>Reed, Kate</au><au>Herbert, Ben R.</au><au>Breen, Edmond J.</au><au>Copeman, Michael C.</au><au>Dunn, Rosanne D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer J</stitle><addtitle>Blood Cancer J</addtitle><date>2019-07-31</date><risdate>2019</risdate><volume>9</volume><issue>8</issue><spage>58</spage><epage>5</epage><pages>58-5</pages><artnum>58</artnum><issn>2044-5385</issn><eissn>2044-5385</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31366914</pmid><doi>10.1038/s41408-019-0217-5</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2044-5385 |
| ispartof | Blood cancer journal (New York), 2019-07, Vol.9 (8), p.58-5, Article 58 |
| issn | 2044-5385 2044-5385 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668455 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals; Nature Free; PubMed Central |
| subjects | 13/1 13/21 59/78 631/250/249/1623 631/67/1059/2325 631/67/1990/804 631/67/327 Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - pharmacokinetics Biomedical and Life Sciences Biomedicine Cancer Research Correspondence Dose-Response Relationship, Drug Hematology Humans Immunoglobulin kappa-Chains - immunology Middle Aged Monoclonal antibodies Multiple Myeloma - drug therapy Multiple Myeloma - immunology Multiple Myeloma - microbiology Multiple Myeloma - pathology Oncology Prognosis Tissue Distribution |
| title | A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A13%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20preliminary%20study%20of%20the%20anti-%CE%BA%20myeloma%20antigen%20monoclonal%20antibody%20KappaMab%20(MDX-1097)%20in%20pretreated%20patients%20with%20%CE%BA-restricted%20multiple%20myeloma&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Spencer,%20Andrew&rft.date=2019-07-31&rft.volume=9&rft.issue=8&rft.spage=58&rft.epage=5&rft.pages=58-5&rft.artnum=58&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/s41408-019-0217-5&rft_dat=%3Cproquest_pubme%3E2267390925%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2267390925&rft_id=info:pmid/31366914&rfr_iscdi=true |